Of Catalent’s (CTLT) more than 50 global sites, Novo Holdings intends to sell three Catalent fill-finish sites and related assets acquired in the merger to Novo Nordisk (NOV), in which Novo Holdings has a controlling interest, shortly after the closing of the merger. These three sites are located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium. This transaction is aligned with Novo Holdings’ strategy of investing in established life science companies with strong long-term potential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTLT:
- Catalent price target raised to $58 from $55 at RBC Capital
- Catalent Shareholders Approve Key Proposals at Annual Meeting
- Catalent’s 2023 Shareholder Meeting Approves Incentive Plan Amendment
- Early notable gainers among liquid option names on January 26th
- Catalent price target raised to $47 from $45 at Barclays